Invo Fertility, Inc. (IVF) Stock Price & Analysis

Invo Fertility, Inc. (IVF) rose 0.16% to USD 0.99 as of September 8, 2026 at 07:37 UTC, according to Nexqual real-time market data.

IVF last closed at USD 0.99; the session ranged USD 0.97–0.99 on volume of 187,818 shares. Market capitalization is —, with a 52-week range of USD 0.9–84.4 (NCM). Source: Nexqual, September 8, 2026 at 07:37 UTC.

Key Statistics (as of September 8, 2026 at 07:37 UTC)

Technical Analysis (IVF)

Nexqual's technical model rates IVF "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 07:37 UTC.

From Invo Fertility, Inc.'s Latest SEC 10-K Filing (filed 2026-06-02)

Key Strengths & Strategy (as disclosed to the SEC)

• These include laws that prohibit the following:     These laws are subject to extensive and increasing enforcement by numerous federal, state, and local government agencies including the Office of Inspector General, the Department of Justice, the Centers for Medicare & Medicaid Services, and various state authorities.
• The SEC allows us to disclose important information by referring to it in that manner.
• Primarily, our INVO Centers seek to employ local, reputable physicians with strong ties to the OBGYN community.   INVOcell Device   Historically, our approach to marketing INVOcell was focused on identifying partners within targeted geographic regions that we believe could best support our efforts to expand access to advanced fertility treatment using the INVOcell and IVC procedure for the large number of underserved infertile people around the world.

Partnerships

• The total purchase price was approximately $760,000, consisting of $360,000 in cash, of which $210,000 was paid at closing, and $400,000 in Series D Preferred Stock.   As part of the acquisition structure, we acquired the clinic's non-medical business assets through Wood Violet, while the clinic's medical assets were acquired by Fertility, P.A., which entered into a long-term Management Services Agreement with Wood Violet.
• On the same date, we entered into an inducement letter agreement with FNL (the "AIR Exercise and Reload Agreement"), pursuant to which FNL exercised its Additional Investment Right to acquire 1,800 shares of Series C-2 Preferred with an aggregate stated value of $1,800,000 in exchange for $1,800,000 of principal, plus accrued and unpaid interest, under the Amended and Restated Debenture.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 07:37 UTC. This page is informational and not investment advice.